Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non-Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results Database

被引:96
|
作者
Osarogiagbon, Raymond U. [1 ]
Yu, Xinhua [2 ]
机构
[1] Boston Baskin Canc Fdn, Baptist Canc Ctr, Multidisciplinary Thorac Oncol Program, Memphis, TN USA
[2] Univ Memphis, Sch Publ Hlth, Dept Epidemiol & Biostat, Memphis, TN 38152 USA
关键词
Non-small-cell lung cancer; Surgical resection; Mediastinal lymph nodes; Quality of care; Outcome of care; Staging; LONG-TERM SURVIVAL; PULMONARY RESECTION; SURGICAL RESECTION; SURGEON SPECIALTY; RANDOMIZED-TRIAL; LYMPHADENECTOMY; OUTCOMES; NUMBER; CLASSIFICATION; DISSECTION;
D O I
10.1097/JTO.0b013e31827457db
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pathologic nodal stage is the key prognostic factor in resectable non-small-cell lung cancer (NSCLC). Mediastinal lymph node (MLN) metastasis connotes a poor prognosis. Yet, some NSCLC resections exclude MLN examination. Methods: We analyzed U.S. Surveillance, Epidemiology, and End Results program data from 1998 to 2002 to quantify the long-term survival impact of failure to examine MLN in resected NSCLC. We used Kaplan-Meier methods to compare the unadjusted survival difference between patients with, and without, MLN examination, and Cox proportional hazards and competing risk models to serially adjust for the impact of risk factors on survival differences. Results: Sixty-two percent of patients with pathologic N0 or N1 NSCLC had no MLN examined. Overall 5-year survival rates were 52% for those with, versus 47% for those without, MLN examination; lung cancer-specific survival rates were 63% versus 58% respectively (p < 0.001); nonlung cancer mortality was identical between cohorts. Adjusting for potential confounders, MLN examination was associated with a 7% reduction in all-cause mortality (hazard ratio, 0.93; confidence interval, 0.88-0.97; p = 0.002), and 11% reduction in lung cancer-specific mortality (hazard ratio, 0.89; 95% confidence interval, 0.84-0.95; p < 0.001) rates. The excess risk in 1 year's cohort of U. S. lung resections was 3150 lives over 5 years. Conclusions: Failure to examine MLN was a common practice in MLN-negative NSCLC resections, which significantly impaired long-term survival. Efforts to understand the etiology of this quality gap, and measures to eliminate it, are warranted.
引用
收藏
页码:1798 / 1806
页数:9
相关论文
共 50 条
  • [21] Surgical choice for patients with stage I non-small-cell lung cancer ≤2 cm: an analysis from surveillance, epidemiology, and end results database
    Liang Wu
    Weigang Zhao
    Tangbing Chen
    Yi Yang
    Journal of Cardiothoracic Surgery, 16
  • [22] Mediastinal lymph node dissection in surgical treatment for early stage non-small-cell lung cancer: lobe-specific or systematic?
    Adachi, Hiroyuki
    Maehara, Takamitsu
    Nakayama, Haruhiko
    Masuda, Munetaka
    JOURNAL OF THORACIC DISEASE, 2017, 9 (09) : 2728 - 2731
  • [23] Trimodality therapy for patients with stage III non-small-cell lung cancer: A comprehensive surveillance, epidemiology, and end results analysis
    Grzywacz, Vincent P.
    Quinn, Thomas J.
    Almahariq, Muayad F.
    Siddiqui, Zaid A.
    Kim, Sang W.
    Guerrero, Thomas M.
    Stevens, Craig W.
    Grills, Inga S.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 32
  • [24] Surgical modality for stage IA non-small cell lung cancer among the elderly: analysis of the Surveillance, Epidemiology, and End Results database
    Wang, Weixi
    Sun, Yan
    Li, Huiting
    Bao, Minwei
    Liu, Xiaogang
    Jiang, Gening
    Ye, Cong
    Hu, Yu
    JOURNAL OF THORACIC DISEASE, 2020, 12 (11) : 6731 - 6742
  • [25] Polymorphisms in the CASPASE Genes and Survival in Patients With Early-Stage Non-Small-Cell Lung Cancer
    Yoo, Seung Soo
    Choi, Jin Eun
    Lee, Won-Kee
    Choi, Yi-Young
    Kam, Sin
    Kim, Min Jung
    Jeon, Hyo-Sung
    Lee, Eung-Bae
    Kim, Dong Sun
    Lee, Myung-Hoon
    Kim, In-San
    Jheon, Sanghoon
    Park, Jae Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5823 - 5829
  • [26] Perioperative pembrolizumab for early-stage non-small-cell lung cancer
    Bastin, Tom
    Thomas, Quentin Dominique
    BULLETIN DU CANCER, 2024, 111 (11) : 1000 - 1002
  • [27] Improving Survival for Stage IV Non-small Cell Lung Cancer A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005
    Morgensztern, Daniel
    Waqar, Saiama
    Subramanian, Janakiraman
    Gao, Feng
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (12) : 1524 - 1529
  • [28] The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non-Small-Cell Lung Cancer
    Qiu, Chen
    Dong, Wei
    Su, Benhua
    Liu, Qi
    Du, Jiajun
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (04) : 429 - 435
  • [29] Variations in Surgeon Treatment Recommendations for Lobectomy in Early-Stage Non-Small-Cell Lung Cancer by Patient Age and Comorbidity
    Rogers, Selwyn O., Jr.
    Gray, Stacy W.
    Landrum, Mary Beth
    Klabunde, Carrie N.
    Kahn, Katherine L.
    Fletcher, Robert H.
    Clauser, Steven
    Tisnado, Diana
    Doucette, William
    Keating, Nancy L.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) : 1581 - 1588
  • [30] Long-term results of robotic anatomical segmentectomy for early-stage non-small-cell lung cancer
    Duy Nguyen
    Gharagozloo, Farid
    Tempesta, Barbara
    Meyer, Mark
    Gruessner, Angelika
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2019, 55 (03) : 427 - 433